Patients who have Rheumatoid Arthritis and start treatment with HUMIRA in normal clinical settings according to label are documented. The follow-up observation period is planned for 5 years and is focused on safety information and maintenance of efficacy during normal clinical settings. The physicians will follow-up the patient via regular office visits at intervals as determined by routine clinical practice or as recommended by national guidelines.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01078090?cond=%22Arthritis%22&lup_s=07/14/2011&lup_d=30
